Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
| ▸ | CCR3 | P51677 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2216397 | 0.83 | MAPK14 (0.64) | MGLLMAPK14CCR3CHRM2CNR2 | |
| SCHEMBL8445412 | 0.82 | KMT2A (0.69) | MAPK14CHRM2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3210544 | 0.80 | MAPK14 (0.65) | MGLLMAPK14L3MBTL1CCR5GAA | |
| SCHEMBL13825981 | 0.78 | CHRM2 (0.57) | MGLLMAPK14CCR3CHRM2CNR2 | |
| SCHEMBL3944989 | 0.78 | CHRM2 (0.58) | CHRM2SMN1; SMN2HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL27787032 | 0.78 | CCR3 (0.49) | MGLLMAPK14CCR3CHRM2HRH3 | |
| SCHEMBL2036317 | 0.78 | MAPK14 (0.62) | MGLLMAPK14CCR3SMN1; SMN2MEN1 | |
| SCHEMBL16002958 | 0.78 | MAPK14 (0.56) | MGLLMAPK14CCR3CHRM2CNR2 | |
| SCHEMBL30294873 | 0.77 | MGLL (1.00) | MGLL | |
| SCHEMBL21121265 | 0.77 | MGLL (1.00) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101605757-A | Be used for (indoles-4-yl) of obesity treatment-or (indoles-5-yl)-piperazinyl methanone derivatives | HOFFMANN LA ROCHE (CH) | 2009-12-16 | — | — | CN | disclosed |
| EP-2118057-A1 | (INDOL-4-YL)- OR (INDOL-5-YL)-PIPERAZINYLMETHANONE DERIVATIVES FOR THE TREATMENT OF OBESITY | F. Hoffmann-Roche AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| US-7557108-B2 | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones | HOFFMANN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557108-B2 | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones | HOFFMANN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557108-B2 | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones | HOFFMANN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| WO-2008095820-A1 | (INDOL-4-YL)- OR (INDOL-5-YL)-PIPERAZINYLMETHANONE DERIVATIVES FOR THE TREATMENT OF OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095820-A1 | (INDOL-4-YL)- OR (INDOL-5-YL)-PIPERAZINYLMETHANONE DERIVATIVES FOR THE TREATMENT OF OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| US-20080188486-A1 | (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188486-A1 | (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188486-A1 | (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188486-A1 | (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES | HRH4, HRH3, H1-3 | MGLL 4213/4885MAPK14 3325/4885CCR3 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.